Clinical trial • Not applicable • Other
ROPIVACAINE HYDROCHLORIDE for Periacetabular osteotomy
Not applicable trial of ROPIVACAINE HYDROCHLORIDE for Periacetabular osteotomy.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Periacetabular osteotomy
- Trial Stage
- Not applicable
- Drug Modality
- Small molecule|Other
Key dates
- Initial CTIS Submission Date
- 30-04-2024
- First CTIS Authorization Date
- 25-06-2024
Trial design
Randomised, ropivacaine kabi 5 mg/ml solution for injetion (active) — perineural use; max total dose 100 mg (dose schedule not further specified). comparator: saline (placebo) — perineural use; max total volume 20 ml.-controlled Not applicable trial across 1 site in Denmark.
- Randomised
- Yes
- Comparator
- Ropivacaine Kabi 5 mg/ml solution for injetion (active) — perineural use; max total dose 100 mg (dose schedule not further specified). Comparator: SALINE (placebo) — perineural use; max total volume 20 ml.
- Target Sample Size
- 90
- Trial Duration For Participant
- 1
Eligibility
Recruits 90 Only adults (Patients ≥ 18 years old). Informed consent required. Vulnerable population not selected. No assent or minor consent procedures described..
- Vulnerable Population
- Only adults (Patients ≥ 18 years old). Informed consent required. Vulnerable population not selected. No assent or minor consent procedures described.
Inclusion criteria
- {"criterion_text":"- Patients ≥ 18 years old\n- Informed consent\n- Scheduled for periacetabular osteotomy under general anesthesia with intubation\n- American Society of Anesthesiologists (ASA) physical status classification I to III\n- Can read and understand Danish"}
Exclusion criteria
- {"criterion_text":"- Known allergy to ropivacaine\n- Daily use of opioids, gabapentin or tricyclic antidepressant (regardless of dose) within the last four weeks prior to surgery\n- Contraindications to Celocoxib, NSAIDs or paracetamol"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Area under curve (AUC) of pain reported on a numeric rating scale (NRS) from 0 to 10 during the first 24 hours postoperatively","definition_or_measurement_approach":"Pain reported on a numeric rating scale (NRS) from 0 to 10; AUC calculated during the first 24 hours postoperatively"}
Secondary endpoints
- {"endpoint_text":"- The number of patients reporting moderate to severe pain at rest [>3 out of 10 on a numeric rating scale (NRS) from 0 to 10] at any point in the immediate postoperative phase (from arrival at the PACU until transfer to the ward). NRS will be assessed upon arrival at the PACU and each 30 minutes.","definition_or_measurement_approach":"NRS assessed upon arrival at the PACU and every 30 minutes; count of patients reporting NRS >3 at any point in immediate postoperative phase (arrival at PACU until transfer to ward)"}
- {"endpoint_text":"- Pain during during mobilization (from laying down in bed till standing on the floor) assessed on a NRS at 5 hours after extubation","definition_or_measurement_approach":"NRS assessment at 5 hours after extubation during mobilization (from lying in bed until standing and walking 5 meters)"}
- {"endpoint_text":"- Opioid use from tracheal extubation until 24 hours postoperatively","definition_or_measurement_approach":"Measurement of opioid consumption from tracheal extubation until 24 hours postoperatively"}
Recruitment
- Planned Sample Size
- 90
- Recruitment Window Months
- 30
- Consent Approach
- Informed consent required from participants. Participants must be ≥18 years old and able to read and understand Danish. No assent or minor consent procedures described. Contact for study/public and scientific queries: Matias Vested (matias.vested@regionh.dk).
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 90
Denmark
- Earliest CTIS Part Ii Submission Date
- 05-06-2024
- Latest Decision Or Authorization Date
- 25-06-2024
- Processing Time Days
- 20
- Number Of Sites
- 1
- Number Of Participants
- 90
Sites
- Site Name
- Rigshospitalet
- Department Name
- Anaesthesia HOC
- Principal Investigator Name
- Matias Vested
- Principal Investigator Email
- matias.vested@regionh.dk
- Contact Person Name
- Matias Vested
- Contact Person Email
- matias.vested@regionh.dk
- Number Of Participants
- 90
Sponsor
Primary sponsor
- Full Name
- Rigshospitalet
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"GCP-enheden ved Københavns Universitetshospital","duties_or_roles":"Sponsor duties code: 1","organisation_type":"Health care"}
Investigational products
- Investigational Product Name
- Ropivacaine Kabi 5 mg/ml solution for injetion
- Active Substance
- ROPIVACAINE HYDROCHLORIDE
- Modality
- Small molecule
- Routes Of Administration
- PERINEURAL USE
- Route
- PERINEURAL USE
- Authorisation Status
- Authorised (marketing authorisation MA1123/03103)
- Maximum Dose
- 100 mg
- Investigational Product Name
- SALINE
- Active Substance
- SALINE
- Modality
- Other
- Routes Of Administration
- PERINEURAL USE
- Route
- PERINEURAL USE
- Authorisation Status
- No marketing authorisation (placebo/unlicensed)
- Maximum Dose
- 20 ml
Related trials
Other published trials that may interest you.